For instance, In a study on psoriasis patients, the use of TNF-α inhibitors increased overall infection and upper respiratory tract infection by up to 7% compared with placebo, higher than the rates with IL-17 and IL-12/23 inhibitors (Lebwohl et al., 2020). This evidence concerns the gene IL17A and Recurrent upper respiratory tract infections.